Due to the ability of the blood–brain barrier (BBB) to prevent the entry of drugs into the brain,
it is a challenge to treat central nervous system disorders pharmacologically. The …

Recently, owing to well-controlled release, enhanced distribution and increased
permeability, nanocarriers used for alternative drug and food-delivery strategies have …

The treatment of various central nervous system (CNS) diseases has been challenging,
despite the rapid development of several novel treatment approaches. The blood–brain …

Many existing chemotherapeutic drugs, repurposed drugs and newly developed small-
molecule anticancer compounds have high lipophilicity and low water-solubility. Currently …

Combinations of drugs promoting anti-angiogenesis and apoptosis effects are meaningful
for cancer therapy. In the present study, dual peptides-modified liposomes were designed by …

The treatment of a brain glioma is still one of the most difficult challenges in oncology. To
effectively treat brain glioma and reduce the side effects, drugs must be transported across …

High-grade gliomas are still characterized by a poor prognosis, despite recent advances in
surgical treatment. Chemotherapy is currently practiced after surgery, but its efficacy is …

The blood–brain barrier (BBB) limits the access of substances to the central nervous system
(CNS) which hinders the treatment of pathologies affecting the brain and the spinal cord …

Gliomas are hard to treat because of the two barriers involved: the blood–brain barrier and
blood–tumor barrier. In this study, a dual-targeting ligand, angiopep-2, and an activatable …

The integrin α v β 3 receptor and Lactoferrin receptor (LfR) are over-expressed in both
cerebral microvascular endothelial cells and glioma cells. RGD tripeptide and Lf can …